Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

Investigators have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without causing unwanted mutations. The system can be formulated completely as ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

Dr. Michael Welsh, a longtime University of Iowa physician-scientist, has been named a 2025 recipient of the prestigious ...

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without ...

primary care providers and genetic counselors. The United States Cystic Fibrosis Foundation released the first guideline on newborn screening for cystic fibrosis (CF), in order to improve timely ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Newborn screening guidelines for cystic fibrosis recommend comprehensive genetic testing to ensure timely diagnosis across ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

US biotech company Vertex Pharmaceuticals (Nasdaq: VRTX) has received European Commission approval to extend the use of its ...